MedPath

panitumumab

Generic Name
panitumumab
Brand Names
Vectibix
Drug Type
Biotech
CAS Number
339177-26-3
Unique Ingredient Identifier
6A901E312A

Overview

Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.

Indication

美国FDA批准:用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。

Associated Conditions

  • Metastatic Colorectal Cancer (CRC)

Research Report

Published: Jul 17, 2025

Panitumumab (Vectibix®): A Comprehensive Monograph on a Targeted Therapy for Metastatic Colorectal Cancer

Executive Summary and Key Findings

Panitumumab, marketed under the brand name Vectibix®, is a cornerstone of targeted therapy for metastatic colorectal cancer (mCRC). It is a recombinant, fully human IgG2 kappa monoclonal antibody that functions as a high-affinity antagonist of the human epidermal growth factor receptor (EGFR).[1] By competitively inhibiting the binding of endogenous ligands like EGF and TGF-α, panitumumab blocks the downstream signaling cascades—primarily the RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways—that drive tumor cell proliferation, survival, and angiogenesis.[3] Its efficacy is critically dependent on the molecular profile of the tumor. The paramount finding from over a decade of clinical research is that panitumumab provides benefit exclusively to patients with wild-type

RAS (both KRAS and NRAS) tumors, and its use in RAS-mutant disease is associated with a lack of benefit and potential harm.[5]

Pivotal clinical trials have precisely defined its role in the mCRC treatment algorithm. The PRIME study established its efficacy in the first-line setting in combination with FOLFOX chemotherapy for RAS wild-type patients, demonstrating significant improvements in both progression-free survival (PFS) and overall survival (OS).[7] The ASPECCT trial confirmed its non-inferiority to the chimeric anti-EGFR antibody cetuximab in the chemorefractory setting, establishing it as a valid therapeutic alternative.[9] More recently, the PARADIGM trial provided practice-changing evidence that for patients with left-sided,

RAS wild-type tumors, first-line treatment with panitumumab plus FOLFOX is superior to bevacizumab plus FOLFOX in extending overall survival, solidifying primary tumor location as a key predictive biomarker.[11] In a strategic reversal of its contraindication in

Continue reading the full research report

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
2009/07/07
Phase 2
Completed
Centre Jean Perrin
2009/05/07
Phase 2
Completed
2009/04/10
Phase 1
Completed
2009/03/13
Phase 2
Completed
2009/03/02
Not Applicable
Completed
2009/02/12
Phase 2
Completed
2009/02/04
Phase 2
Completed
Weijing Sun, MD, FACP
2009/01/19
Phase 3
Terminated
2009/01/09
Phase 2
Completed
2008/11/26
Phase 2
Completed
Robert Ferris

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

View More TGA Approvals

Sign in to access additional TGA-approved drug information with detailed regulatory data.

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.